Serotonin Reuptake Inhibitors in Pregnancy: Can Genes Help Us in Predicting Neonatal Adverse Outcome?

Table 3

Genotypes as possible regulators of perinatal serotoninergic symptoms after in utero exposure to SSRIs—courtesy of Oberlander 2008—Molecular Psychiatry. Frequency (%) of PNA symptoms by SLC6A4 genotype and SRI exposure.

SLC6A4 genotype	ll		ls		ss
	No exposure; (𝑛=14)	SRI exposure; (𝑛=14)	No exposure; (𝑛=22)	SRI exposure; (𝑛=16)	No exposure; (𝑛=11)	SRI exposure; (𝑛=7)
Tachycardia (>160 bpm)	14.3	57.1	13.6	25.0	27.3	14.3
Bradycardia (<100 bpm)	7.1	0.0	4.5	0.0	0.0	0.0
Tachypnea breathing (>60 min)	14.3	57.1*	13.6	25.0	27.3	14.3
Respiratory distress	14.3	50.0*	9.1	43.8	9.1	42.9
Itteriness	0.0	35.7*	9.1	25.0	9.1	57.1*
Increased motor tone	0.0	14.3	0.0	0.0	0.0	42.9*
Hypoglycemia (<3.3 mmol/L)	7.1	21.4	9.1	25.0	9.1	14.3
Hyperglycemia (>7 mmol/L)	0.0	7.1	0.0	0.0	0.0	14.3

PNA: poor neonatal adaptation; SRI: serotonin reuptake inhibitors. *Compared with no exposure on Pearson’s 𝜒² (all 𝑃<0.05).